Piramal Pharma: 7 Stock Signals Investors Are Watching Right Now

Piramal Pharma stock signals are unusually layered right now, with the company trading at Rs 210.90, 9.1% below its 52-week high of Rs 231.93 and 59.4% above its 52-week low of Rs 132.30. Piramal Pharma is a well tracked name in the contract development, manufacturing and pharmaceuticals space, and no single headline captures where the stock stands today.

This article does not make a buy, hold or sell call on Piramal Pharma. It lays out seven signals investors commonly watch, each sourced from the company's latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.

Click Here – Get Free Investment Predictions

Piramal Pharma Stock at a Glance

Before going through each of the seven Piramal Pharma stock signals in detail, the snapshot below sets the starting point on price, valuation and balance sheet strength.

Metric	Value
Piramal Pharma CMP	Rs 210.90 (NSE, 23 Sep 2026)
52-Week High	Rs 231.93 (7 September 2026)
52-Week Low	Rs 132.30 (23 March 2026)
Market Capitalisation	Rs 27,978 crore
P/E Ratio	NA (Sector P/E 38.56)
P/B Ratio	3.43
Debt to Equity	0.7
Return on Equity	-3.58%

1. Earnings Trend at Piramal Pharma

Piramal Pharma posted trailing-twelve-month revenue of Rs 9,450 crore versus Rs 9,082 crore a year earlier, while net profit moved to Rs -314 crore from Rs -326 crore, a change of 3.8% on the year. The most recent quarter added Rs 2,359.33 crore in revenue, a change of 18.4% year on year, against Rs -69.39 crore in net profit versus Rs -81.70 crore a year earlier.

the company narrowed its net loss year on year in the June 2026 quarter as revenue grew close to 18%, with the trailing-twelve-month loss also narrower than a year earlier, though the business remains loss making overall. This is the first of the seven Piramal Pharma stock signals worth tracking closely into the next results.

2. FII Holding in Piramal Pharma

A full quarterly FII holding series was not available from the data source used here for Piramal Pharma. Where that is the case, the most reliable next step is to check the company's latest exchange filing directly, since a single-quarter snapshot can be misleading without the trend around it.

This is worth revisiting once the next quarterly shareholding disclosure is filed.

3. Promoter Holding in Piramal Pharma

Promoter holding in Piramal Pharma promoter and institutional shareholding figures were not available from the data source used here; investors can check the company's latest exchange filing directly.

This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.

4. Debt Position at Piramal Pharma

Piramal Pharma's debt to equity ratio stands at 0.7, one of the balance sheet metrics worth tracking alongside the earnings trend above. A lower or stable ratio generally gives more room to fund growth without leaning further on external borrowing, while a rising one is worth watching for its effect on finance costs.

This debt signal should be read alongside the valuation and corporate development signals below rather than in isolation, since capital raising plans can shift the picture from one quarter to the next.

5. Valuation of Piramal Pharma Shares

Piramal Pharma's trailing P/E ratio is not meaningful right now given its financial profile, so conventional valuation multiples carry limited weight for this stock. The sector average P/E of 38.56 can still serve as a reference point for how peers in the contract development, manufacturing and pharmaceuticals space are priced.

For a stock in this situation, the earnings trend in Signal 1 and the corporate developments in Signal 7 carry more weight than a standard valuation multiple until the underlying financial position normalises.

6. Technical Trend on the Piramal Pharma Chart

The stock last traded around Rs 210.90, above its short-term average of about Rs 210.50, pointing to near-term strength. The 14-day RSI reads close to 36, in neutral territory. The MACD line sits below its signal line, a bearish momentum bias.

Over the past year the stock is currently 9.1% below its 52-week high of Rs 231.93 and 59.4% above its 52-week low of Rs 132.30. A sustained move back above its recent average would be an early technical sign of stabilisation.

7. Corporate Developments at Piramal Pharma

Piramal Pharma, which operates across the US, Europe, Japan, India and other markets, has seen its share price rise close to 53% over the past six months as its contract development and manufacturing, complex hospital generics and consumer healthcare businesses show signs of recovery.

Check the Univest Screener for live fundamentals

What These Piramal Pharma stock signals Mean Together

None of these seven signals on its own settles the debate on Piramal Pharma. Reading them as a set, rather than picking out any single one, is the more balanced way to approach the stock right now. The earnings trend, shareholding pattern, balance sheet position, valuation, technical setup and corporate developments each add one piece of the picture, and they do not all point the same way at the same time.

Investors weighing Piramal Pharma would do well to watch the next quarterly results for a read on where margins and profit are heading, alongside the next shareholding pattern update for any shift in institutional positioning. Reading these Piramal Pharma stock signals together, rather than in isolation, remains the more balanced approach. As with any single stock, price movements can be volatile and past trends do not guarantee future performance.

For context, investors following Piramal Pharma often look at how the stock has moved through previous earnings cycles, how peer companies in the same space have reacted to similar corporate developments, and whether broader market conditions such as interest rate moves, sector-wide policy shifts or commodity price swings have played a larger role than company-specific news. None of these broader factors replace the seven signals above, but they help explain why a stock can move sharply even when no single company-specific trigger is visible in the data. Reading a stock's price action purely in isolation, without this wider lens, can lead to drawing conclusions that do not hold up once the next quarter's numbers or the next shareholding disclosure comes in. Investors are generally better served treating each of these seven factors as one input among several, updated on a rolling basis as new disclosures arrive, rather than as a one-time checklist filled in once and then set aside for the rest of the year without a further look.

Also Read: HDFC Bank: 7 Stock Signals Investors Are Watching Right Now

Conclusion

Piramal Pharma currently sits at the intersection of several moving parts, from earnings and shareholding to valuation and chart trend, and that is exactly what the seven signals above are meant to surface. This article does not recommend buying, holding or selling Piramal Pharma shares, and readers should form their own view based on their own research and risk appetite.

Download the Univest iOS App or Univest Android App to track Piramal Pharma live price and more such signal based stock research.

FAQs on Piramal Pharma Stock Signals

Why is Piramal Pharma share price where it is right now?

Ans. Piramal Pharma shares are trading 9.1% below their 52-week high of Rs 231.93 and 59.4% above their 52-week low of Rs 132.30, shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.

What is Piramal Pharma's current FII holding?

Ans. A full quarterly FII holding series was not available for this article; check the company's latest exchange filing directly.

Is Piramal Pharma's debt position a concern right now?

Ans. The debt to equity ratio stands at 0.7.

What is the promoter holding in Piramal Pharma?

Ans. promoter and institutional shareholding figures were not available from the data source used here; investors can check the company's latest exchange filing directly.

Is Piramal Pharma expensive compared to its sector?

Ans. Piramal Pharma's P/E ratio is not meaningful right now given its financial profile; the sector average P/E of 38.56 is a reference point for peers.

What recent corporate developments are relevant to Piramal Pharma?

Ans. Piramal Pharma, which operates across the US, Europe, Japan, India and other markets, has seen its share price rise close to 53% over the past six months as its contract development and manufacturing, complex hospital generics and consumer healthcare businesses show signs of recovery.

What do the technical charts suggest about Piramal Pharma right now?

Ans. The stock is trading above its short-term average of about Rs 210.50, pointing to near-term strength, with its MACD line below its signal line, a bearish momentum bias.

Should investors buy Piramal Pharma shares at current levels?

Ans. This article does not offer a buy, hold or sell recommendation. It lays out seven Piramal Pharma stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.